{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=SOLID+TUMORS&page=33",
    "query": {
      "condition": "SOLID TUMORS",
      "page": 33
    },
    "page_size": 10
  },
  "pagination": {
    "page": 33,
    "page_size": 10,
    "total_count": 5453,
    "total_pages": 546,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=SOLID+TUMORS&page=34&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=SOLID+TUMORS&page=32&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T12:15:25.450Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02800889",
      "title": "Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Solid Tumor (Excluding CNS)"
      ],
      "interventions": [
        {
          "name": "Pixantrone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CTI BioPharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "6 Months to 21 Years"
      },
      "enrollment_count": 0,
      "start_date": "2016-10-24",
      "completion_date": "2018-07-10",
      "has_results": false,
      "last_update_posted_date": "2020-01-29",
      "last_synced_at": "2026-10-16T12:15:25.450Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02800889"
    },
    {
      "nct_id": "NCT01461538",
      "title": "Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoid Leukemia",
        "Acute Myeloid Leukemia",
        "Anemia, Refractory, With Excess of Blasts",
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "brentuximab vedotin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 84,
      "start_date": "2011-10",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2016-03-04",
      "last_synced_at": "2026-10-16T12:15:25.450Z",
      "location_count": 29,
      "location_summary": "Birmingham, Alabama • Duarte, California • Oxnard, California + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01461538"
    },
    {
      "nct_id": "NCT03217747",
      "title": "Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Castration-Resistant Prostate Carcinoma",
        "Malignant Solid Neoplasm",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Prostate Carcinoma",
        "Prostate Carcinoma Metastatic in the Bone",
        "Refractory Malignant Solid Neoplasm",
        "Stage IV Prostate Cancer AJCC v8",
        "Stage IVA Prostate Cancer AJCC v8",
        "Stage IVB Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Ivuxolimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Utomilumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 173,
      "start_date": "2017-08-02",
      "completion_date": "2026-04-30",
      "has_results": true,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-10-16T12:15:25.450Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03217747"
    },
    {
      "nct_id": "NCT06172478",
      "title": "A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Melanoma",
        "Head and Neck Cancer",
        "Gastric Cancer",
        "Ovarian Carcinoma",
        "Cervical Cancer",
        "Endometrial Cancer",
        "Bladder Cancer",
        "Esophageal Cancer",
        "Pancreatic Carcinoma",
        "Prostate Cancer",
        "Non-small Cell Lung Cancer (NSCLC)",
        "Lung Cancer",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "HER3-DXd",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 740,
      "start_date": "2024-02-26",
      "completion_date": "2028-10-10",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-16T12:15:25.450Z",
      "location_count": 13,
      "location_summary": "Duarte, California • New Haven, Connecticut • Kissimmee, Florida + 10 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06172478"
    },
    {
      "nct_id": "NCT02223052",
      "title": "Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hematological Neoplasms",
        "Non-Hodgkin's Lymphoma",
        "Hodgkin's Lymphoma",
        "Lymphoma",
        "Multiple Myeloma",
        "Acute Myeloid Leukemia",
        "Leukemia",
        "Myelodysplastic Syndromes",
        "Neoplasms",
        "Melanoma",
        "Breast Cancer",
        "Metastatic Breast Cancer",
        "Non-Small Cell Lung Cancer",
        "Small Cell Lung Cancer",
        "Renal Cell Carcinoma",
        "Glioblastoma Multiforme",
        "Osteosarcoma",
        "Sarcoma",
        "Thyroid Cancer",
        "Genitourinary"
      ],
      "interventions": [
        {
          "name": "CC-486",
          "type": "DRUG"
        },
        {
          "name": "Vidaza",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2014-10-27",
      "completion_date": "2018-12-18",
      "has_results": false,
      "last_update_posted_date": "2020-05-12",
      "last_synced_at": "2026-10-16T12:15:25.450Z",
      "location_count": 10,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Iowa City, Iowa + 6 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02223052"
    },
    {
      "nct_id": "NCT04089449",
      "title": "A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Recurrent Glioma"
      ],
      "interventions": [
        {
          "name": "PRT811",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Prelude Therapeutics Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 86,
      "start_date": "2019-11-06",
      "completion_date": "2023-03-28",
      "has_results": false,
      "last_update_posted_date": "2023-04-05",
      "last_synced_at": "2026-10-16T12:15:25.450Z",
      "location_count": 11,
      "location_summary": "Denver, Colorado • New Haven, Connecticut • Newark, Delaware + 8 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04089449"
    },
    {
      "nct_id": "NCT06249048",
      "title": "Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "STX-001",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Keytruda®",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Strand Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 108,
      "start_date": "2024-05-03",
      "completion_date": "2028-11",
      "has_results": false,
      "last_update_posted_date": "2025-10-29",
      "last_synced_at": "2026-10-16T12:15:25.450Z",
      "location_count": 6,
      "location_summary": "Scottsdale, Arizona • Beverly Hills, California • Cleveland, Ohio + 3 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06249048"
    },
    {
      "nct_id": "NCT03229278",
      "title": "Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Melanoma",
        "Metastatic Renal Cell Cancer",
        "Recurrent Bladder Carcinoma",
        "Recurrent Classical Hodgkin Lymphoma",
        "Recurrent Head and Neck Squamous Cell Carcinoma",
        "Recurrent Lymphoma",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Renal Cell Carcinoma",
        "Stage III Bladder Cancer",
        "Stage III Lymphoma",
        "Stage III Non-Small Cell Lung Cancer AJCC v7",
        "Stage III Renal Cell Cancer",
        "Stage III Skin Melanoma",
        "Stage IIIA Non-Small Cell Lung Cancer AJCC v7",
        "Stage IIIA Skin Melanoma",
        "Stage IIIB Non-Small Cell Lung Cancer AJCC v7",
        "Stage IIIB Skin Melanoma",
        "Stage IIIC Skin Melanoma",
        "Stage IV Bladder Cancer",
        "Stage IV Lymphoma",
        "Stage IV Non-Small Cell Lung Cancer AJCC v7",
        "Stage IV Renal Cell Cancer",
        "Stage IV Skin Melanoma",
        "Stage IVA Bladder Cancer",
        "Stage IVB Bladder Cancer",
        "Unresectable Head and Neck Squamous Cell Carcinoma",
        "Unresectable Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Enzyme Inhibitor Therapy",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2017-10-03",
      "completion_date": "2022-10-30",
      "has_results": true,
      "last_update_posted_date": "2023-12-06",
      "last_synced_at": "2026-10-16T12:15:25.450Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03229278"
    },
    {
      "nct_id": "NCT00089089",
      "title": "Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hematopoietic/Lymphoid Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "decitabine",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2004-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-07",
      "last_synced_at": "2026-10-16T12:15:25.450Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00089089"
    },
    {
      "nct_id": "NCT02100891",
      "title": "Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ewing Sarcoma",
        "Neuroblastoma",
        "Rhabdomyosarcoma",
        "Osteosarcoma",
        "CNS Tumors"
      ],
      "interventions": [
        {
          "name": "Allogeneic HCT",
          "type": "PROCEDURE"
        },
        {
          "name": "Donor NK Cell Infusion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Monica Thakar",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 15,
      "start_date": "2013-03-20",
      "completion_date": "2020-07-15",
      "has_results": true,
      "last_update_posted_date": "2025-03-19",
      "last_synced_at": "2026-10-16T12:15:25.450Z",
      "location_count": 2,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02100891"
    }
  ]
}